According to the latest update from KRYSTAL-1, adagrasib shows durable efficacy in patients with advanced, previously treated KRASG12C non–small cell lung cancer. At 2 years, approximately one in three patients were still alive, and no new toxicities emerged, indicating that the KRASG12C inhibitor's long-term safety is manageable.

You do not currently have access to this content.